Advertisement

Reactions Weekly

, Volume 1695, Issue 1, pp 193–193 | Cite as

Gefitinib/osimertinib

Development of gefitinib and osimertinib resistance and transformation of the lung adenocarcinoma to small cell lung cancer: 3 case reports
Case report
  • 14 Downloads

Reference

  1. Liam C, et al. Case series of small cell lung cancer transformation as resistance mechanism to epidermal growth factor receptor-tyrosine kinase inhibitor. Journal of Thoracic Oncology 12 (Suppl. 2): S2342 abstr. P3.15-014, No. 11, Nov 2017 [abstract] - MalaysiaGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations